Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

Danny Cohn, internist at Amsterdam UMC and first author of the studyThe results of this double-blind, placebo-controlled portion of the study confirm our promising findings from the phase 1 study, showing dramatic reductions of angioedema swellings following a single-dose treatment with this gene editing based therapy."

Source:Journal reference:

Cohn, D. M., et al. (2024) CRISPR-Based Therapy for Hereditary Angioedema. New England Journal of Medicine. doi.org/10.1056/NEJMoa2405734.